Nearly a year after its ban in the UK, a new survey has revealed that clubbers are still taking designer party drug miaow miaow.
It found that the ban has failed to reduce its availability and might have even driven some users to harder drugs, reports the Telegraph,
A survey by the Independent Scientific Committee on Drugs has found that users have noticed little difference in their ability to get hold of mephedrone, which is nicknamed miaow miaow, since it was banned.
It also showed that 44 percent of those who have used mephedrone said the ban made them more likely to use the Class A party drug ecstasy instead.
It comes after a recent research revealed that 40 new synthetic drugs have flooded into the UK during the past year.
Professor David Nutt, a leading psychopahrmacologist who chairs the committee, said banning mephedrone did not appear to have been effective.
He warned that the move, which came after mephedrone had been linked to a number of deaths that were later found not to be attributable to the drug, could be driving demand for other new drugs.
"It is not at all clear that the ban on mephedrone has helped to reduce harm. The ban has not greatly affected the availability of mephedrone because people were stockpiling before the ban came in but also because it has been very difficult to stop it from coming into the country," said Nutt.
"One of the dangers of the approach that has been taken is that if we ban every new drug without a balanced view, then people will keep making more new drugs to replace them and eventually they will make something that is extremely toxic which, when kids take it, they will die," he said.
"So we could be provoking harm by the way we are handling these new drugs," he added.
The new survey, which questioned 1,500 drug users in an online questionnaire, found that 58 percent of the respondents said they were less likely to use mephedrone since the ban, but 45 percent said they would still try to get hold of it despite the ban and 51 percent said the ban had not affected availability of the drug.
A fifth of those who responded said they had experienced a negative reaction to mephedrone after taking it.
Nutt has now urged the Home Office's Advisory Council on the Misuse of Drugs to review the ban on mephedrone and said future classifications of new drugs need to be informed by scientific evidence on the effects and harm that the drugs can cause.